Sheri Trudeau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sheri Trudeau has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Mei Lu
School of Medicine Michigan State University East Lansing Michigan USA
12 shared publications - Loralee B. Rupp
Center for Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan
8 shared publications - Mark A. Schmidt
Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR 97227, USA
8 shared publications - Meng-Hua Tao
Department of Public Health Sciences, Henry Ford Health, Detroit, USA
8 shared publications - Stuart C. Gordon
Division of Gastroenterology and Hepatology Henry Ford Health Detroit Michigan USA
8 shared publications - Trueman Wu
Department of Public Health Sciences Henry Ford Health Detroit Michigan USA
8 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background:Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers.Methods:A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk.Results:After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers.Conclusions:Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs.Impact:Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background:Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers.Methods:A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk.Results:After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers.Conclusions:Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs.Impact:Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 4 shows characteristics of HCV patients at baseline for breast cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 4 shows characteristics of HCV patients at baseline for breast cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 6 describes distribution of identified primary NHL cases based on morphology type
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 6 describes distribution of identified primary NHL cases based on morphology type
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 2 describes characteristics of HCV patients at baseline for lung cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 2 describes characteristics of HCV patients at baseline for lung cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 1 shows ICD-O-3 codes used to identify interested primary extrahepatic cancers
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 1 shows ICD-O-3 codes used to identify interested primary extrahepatic cancers
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 5 shows characteristics of HCV patients at baseline for prostate cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 5 shows characteristics of HCV patients at baseline for prostate cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 3 describes characteristics of HCV patients at baseline for NHL
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 3 describes characteristics of HCV patients at baseline for NHL
- 28 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2025-2031
Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background: Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers. Methods: A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk. Results: After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers. Conclusions: Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs. Impact: Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- 28 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2025-2031
Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background: Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers. Methods: A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk. Results: After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers. Conclusions: Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs. Impact: Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- 6 July 2023
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 30 (9) , 746-755
Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C
Chronic hepatitis C (HCV) is a primary cause of hepatocellular carcinoma (HCC). Although antiviral treatment reduces risk of HCC, few studies quantify the impact of treatment on long‐term risk in the era of direct‐acting antivirals (DAA). Using data from the Chronic Hepatitis Cohort Study, we evaluated the impact of treatment type (DAA, interferon‐based [IFN], or none) and outcome (sustained virological response [SVR] or treatment failure [TF]) on risk of HCC. We then developed and validated a predictive risk model. 17186 HCV patients were followed until HCC, death or last follow‐up. We used extended landmark modelling, with time‐varying covariates and propensity score justification and generalized estimating equations with a link function for discrete time‐to‐event data. Death was considered a competing risk. We observed 586 HCC cases across 104,000 interval‐years of follow‐up. SVR from DAA or IFN‐based treatment reduced risk of HCC (aHR 0.13, 95% CI 0.08–0.20; and aHR 0.45, 95% CI 0.31–0.65); DAA SVR reduced risk more than IFN SVR (aHR 0.29, 95% CI 0.17–0.48). Independent of treatment, cirrhosis was the strongest risk factor for HCC (aHR 3.94, 95% CI 3.17–4.89 vs. no cirrhosis). Other risk factors included male sex, White race and genotype 3. Our six‐variable predictive model had ‘excellent’ accuracy (AUROC 0.94) in independent validation. Our novel landmark interval‐based model identified HCC risk factors across antiviral treatment status and interactions with cirrhosis. This model demonstrated excellent predictive accuracy in a large, racially diverse cohort of patients and could be adapted for ‘real world’ HCC monitoring.
- 6 July 2023
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 30 (9) , 746-755
Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C
Chronic hepatitis C (HCV) is a primary cause of hepatocellular carcinoma (HCC). Although antiviral treatment reduces risk of HCC, few studies quantify the impact of treatment on long‐term risk in the era of direct‐acting antivirals (DAA). Using data from the Chronic Hepatitis Cohort Study, we evaluated the impact of treatment type (DAA, interferon‐based [IFN], or none) and outcome (sustained virological response [SVR] or treatment failure [TF]) on risk of HCC. We then developed and validated a predictive risk model. 17186 HCV patients were followed until HCC, death or last follow‐up. We used extended landmark modelling, with time‐varying covariates and propensity score justification and generalized estimating equations with a link function for discrete time‐to‐event data. Death was considered a competing risk. We observed 586 HCC cases across 104,000 interval‐years of follow‐up. SVR from DAA or IFN‐based treatment reduced risk of HCC (aHR 0.13, 95% CI 0.08–0.20; and aHR 0.45, 95% CI 0.31–0.65); DAA SVR reduced risk more than IFN SVR (aHR 0.29, 95% CI 0.17–0.48). Independent of treatment, cirrhosis was the strongest risk factor for HCC (aHR 3.94, 95% CI 3.17–4.89 vs. no cirrhosis). Other risk factors included male sex, White race and genotype 3. Our six‐variable predictive model had ‘excellent’ accuracy (AUROC 0.94) in independent validation. Our novel landmark interval‐based model identified HCC risk factors across antiviral treatment status and interactions with cirrhosis. This model demonstrated excellent predictive accuracy in a large, racially diverse cohort of patients and could be adapted for ‘real world’ HCC monitoring.
- 20 March 2023
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 30 (6) , 544-550
Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals
Research suggests a possible link between chronic infection with hepatitis C virus (HCV) and the development of Parkinson's Disease (PD) and secondary Parkinsonism (PKM). We investigated the impact of antiviral treatment status (untreated, interferon [IFN] treated, direct‐acting antiviral [DAA] treated) and outcome (treatment failure [TF] or sustained virological response [SVR]) on risk of PD/PKM among patients with HCV. Using data from the Chronic Hepatitis Cohort Study (CHeCS), we applied a discrete time‐to‐event approach with PD/PKM as the outcome. We performed univariate followed by a multivariable modelling that used time‐varying covariates, propensity scores to adjust for potential treatment selection bias and death as a competing risk. Among 17,199 confirmed HCV patients, we observed 54 incident cases of PD/PKM during a mean follow‐up period of 17 years; 3753 patients died during follow‐up. There was no significant association between treatment status/outcome and risk of PD/PKM. Type 2 diabetes tripled risk (hazard ratio [HR] 3.05; 95% CI 1.75–5.32; p < .0001) and presence of cirrhosis doubled risk of PD/PKM (HR 2.13, 95% CI 1.31–3.47). BMI >30 was associated with roughly 50% lower risk of PD/PKM than BMI p = .0138). After adjustment for treatment selection bias, we did not observe a significant association between HCV patients' antiviral treatment status/outcome on risk of PD/PKM. Several clinical risk factors—diabetes, cirrhosis and BMI—were associated with PD/PKM.
- 20 March 2023
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 30 (6) , 544-550
Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals
Research suggests a possible link between chronic infection with hepatitis C virus (HCV) and the development of Parkinson's Disease (PD) and secondary Parkinsonism (PKM). We investigated the impact of antiviral treatment status (untreated, interferon [IFN] treated, direct‐acting antiviral [DAA] treated) and outcome (treatment failure [TF] or sustained virological response [SVR]) on risk of PD/PKM among patients with HCV. Using data from the Chronic Hepatitis Cohort Study (CHeCS), we applied a discrete time‐to‐event approach with PD/PKM as the outcome. We performed univariate followed by a multivariable modelling that used time‐varying covariates, propensity scores to adjust for potential treatment selection bias and death as a competing risk. Among 17,199 confirmed HCV patients, we observed 54 incident cases of PD/PKM during a mean follow‐up period of 17 years; 3753 patients died during follow‐up. There was no significant association between treatment status/outcome and risk of PD/PKM. Type 2 diabetes tripled risk (hazard ratio [HR] 3.05; 95% CI 1.75–5.32; p < .0001) and presence of cirrhosis doubled risk of PD/PKM (HR 2.13, 95% CI 1.31–3.47). BMI >30 was associated with roughly 50% lower risk of PD/PKM than BMI p = .0138). After adjustment for treatment selection bias, we did not observe a significant association between HCV patients' antiviral treatment status/outcome on risk of PD/PKM. Several clinical risk factors—diabetes, cirrhosis and BMI—were associated with PD/PKM.